Anti-angiogenic therapies for malignant pleural mesothelioma

Bibliography

• Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603
   PubMed Web of Science ®Google Scholar
• Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-90
   Web of Science ®Google Scholar
• Sugarbaker DJ, Flores RM, Jaklitsch MT, Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65
   PubMed Web of Science ®Google Scholar
• Treasure T, Lang-Lazdunski L, Waller D, Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72
   PubMed Web of Science ®Google Scholar
• Mc Aleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2009;75:326-37
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Shin DM, Kindler HL, Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, Favaretto AG, Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443-8
   PubMed Web of Science ®Google Scholar
• Castagneto B, Botta M, Aitini E, Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370-3
   PubMed Web of Science ®Google Scholar
• Santoro A, O'Brien ME, Stahel RA, Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 2008;3:756-63
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, Gianoncelli L, Second-line treatment for malignant pleural mesotelioma. Cancer Treat Rev 2010;36:24-32
   PubMed Web of Science ®Google Scholar
• Zucali PA, Ceresoli GL, De Vincenzo F, Advances in the biology of malignant pleural mesotelioma. Cancer Treat Rev 2011;37:543-58
   PubMed Web of Science ®Google Scholar
• Demirag F, Unsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005;128:3382-7
   PubMed Web of Science ®Google Scholar
• Strizzi L, Catalano A, Vianale G, Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75
   PubMed Web of Science ®Google Scholar
• Linder C, Linder S, Munck-Wikland E, Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998;18:2063-8
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Weyler J, Martin MJ, Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999;189:72-8
   PubMed Web of Science ®Google Scholar
• Ocana A, Amir E, Vera F, Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011;29:254-6
   PubMed Web of Science ®Google Scholar
• Karrison T, Kindler HL, Gandara DR, Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):7526
   Google Scholar
• Li Q, Yano S, Ogino H, The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesotelioma cells in severe combined immunodeficient mice. Clin Cancer Res 2007;13:5918-25
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, Mencoboni M, Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma [abstract S06-3]. Proceedings of the X International Conference of the IMIG (International Mesothelioma Interest Group); Kyoto (Japan); 2010
   Google Scholar
• Dowell J, Taub R, Lan C, A multicenter phase II study of pemetrexed, cisplatin and bevacizumab in patients with advanced malignant mesothelioma. J Clin Oncol 2009;27(15s):abstract 7578
   Google Scholar
• Zalcman G, Margery J, Scherpereel A, IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II-III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol 2010;28(15s):abstract 7020
   Google Scholar
• Carboplatin, bevacizumab and pemetrexed in the first-line treatment of patients with malignant pleural mesothelioma. NCT00604461. Available from: www.ClinicalTrials.gov
   Google Scholar
• Jackman DM, Kindler HL, Yeap BY, Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-14
   PubMed Web of Science ®Google Scholar
• Baas P, Boogerd W, Dalesio O, Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005;48:291-6
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Abraham R, Harvie R, Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma (MM): interim results from two parallel non randomized phase II studies [abstract O-26]. Lung Cancer 2003;41(Suppl 2):S11
   Google Scholar
• Baas P, Buikhuisen W, Dalesio O, A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J Clin Oncol 2011;29:abstract 7006
   Google Scholar
• Kindler HL, Vogelzang NJ, Chien K, SU5416 in Malignant Mesothelioma: a University of Chicago Phase II Consortium Study. Proc Am Soc Clin Oncol 2001;20:abstract 1359
   Google Scholar
• Dubey S, Janne PA, Krug L, A phase II study of sorafenib in malignant mesothelioma. Results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010;5:1655-61
   PubMed Web of Science ®Google Scholar
• Irshad S, Popat R, Shah S, A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18FDG-PET. J Clin Oncol 2010;28(15s):abstract 7038
   Google Scholar
• Mutri V, Pinto C, Giaquinta S, Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma patients: italian SoMe study. J Clin Oncol 2011;29:abstract 7087
   Google Scholar
• Richly H, Henning BF, Kupsch P, Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73
   PubMed Web of Science ®Google Scholar
• Katz SI, Zhou L, Chao G, Sorafenib inhibits ERK1/2 and MCL-IL posphorylation lebels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther 2009;8:2406-16
   PubMed Web of Science ®Google Scholar
• Nowak A, Millward M, Francis R, Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma [abstract S13-1]. Proceedings of the X International Conference of the IMIG (International Mesothelioma Interest Group); Kyoto (Japan); 2010
   Google Scholar
• Laurie SA, Gupta A, Chu Q, Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC clinical trials group. J Thorac Oncol 2011;6:1950-4
   PubMed Web of Science ®Google Scholar
• Chow LQM, Blais N, Jonker DJ, A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol 2011; published online 12 October 2011; doi: 10.1007/s00280-011-1755-0.
   Web of Science ®Google Scholar
• Okamoto I, Shimizu T, Miyazaki M, Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Invest New Drugs 2010; published online 20 October 2010; doi:10.1007/s10637-010-9565-5.
   Web of Science ®Google Scholar
• A study to find the best dose of SU01248 when given with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors. NCT00528619 Available from: www.ClinicalTrials.gov
   Google Scholar
• Jahan T, Gu L, Kratzke R, Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2011; published online 22 December 2011; doi: 10.1016/j.lungcan.2011.11.014
   PubMed Web of Science ®Google Scholar
• Garland LL, Chansky K, Wozniak AJ, Phase II study of cediranib in patients with malignant pleural mesothelioma. SWOG S0509. J Thorac Oncol 2011;6:1938-45
   PubMed Web of Science ®Google Scholar
• Pemetrexed disodium and cisplatin with or without cediranib maleate in treating patients with malignant pleural mesothelioma. NCT01064648 Available from: www.ClinicalTrials.gov
   Google Scholar
• Ogino H, Yano S, Kakiuchi S, Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett 2008;265:55-66
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Zucali PA, Assarat YG, Preclinical emergence of vandetanib as a potent antitumour agent in mesotelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 2011;105:1542-53
   PubMed Web of Science ®Google Scholar
• An efficacy and safety study with vandetanib to treat inoperable or relapsed malignant mesothelioma. NCT00597116 Available from: www.ClinicalTrials.gov
   Google Scholar
• Pazopanib in treating patients with malignant pleural mesothelioma. NCT00459862 Available from: www.ClinicalTrials.gov
   Google Scholar
• Axitinib in malignant mesothelioma (N08CPA). NCT01211275 Available from: www.ClinicalTrials.gov
   Google Scholar
• Buikhuisen W, Griffioen A, Marijt K, Tissue response in patients with MPM after treatment with cisplatin, pemetrexed and axitinib: first results of a feasibility study [abstract. S13-4]. Proceedings of the X International Conference of the IMIG (International Mesothelioma Interest Group); Kyoto (Japan); 2010
   Google Scholar
• Ikuta K, Yano S, Trung VT, E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 2009;15:7229-37
   PubMed Web of Science ®Google Scholar
• Yamada K, Yamamoto N, Yamada Y, Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011;17:2528-37
   PubMed Web of Science ®Google Scholar
• Rangel R, Sun Y, Guzman-Rojas L, Impaired angiogenesis in aminopeptidase N-null mice. PNAS 2007;104:4588-93
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82
   PubMed Web of Science ®Google Scholar
• van Laarhoven HWM, Fiedler W, Desar IME, Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res 2010;16:1315-23
   PubMed Web of Science ®Google Scholar
• Gregorc V, Zucali PA, Santoro A, Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010;28:2604-11
   PubMed Web of Science ®Google Scholar
• NGR015: Study in second line for patients with advanced malignant pleural mesothelioma pretreated with pemetrexed. NCT01098266 Available from: www.ClinicalTrials.gov
   Google Scholar
• Phase II study of NGR-hTNF versus placebo as maintenance treatment in patients with advanced malignant pleural mesothelioma (NGR019). NCT01358084 Available from: www.ClinicalTrials.gov
   Google Scholar
• Edwards JG, Swinson DE, Jones JL, Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003;124:1916-23
   PubMed Web of Science ®Google Scholar
• Cacciotti P, Strizzi L, Vianale G, The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2002;26:189-93
   PubMed Web of Science ®Google Scholar
• Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312
   PubMed Web of Science ®Google Scholar
• Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003;112:1142-51
   PubMed Web of Science ®Google Scholar
• Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest 2003;112:1134-6
   PubMed Web of Science ®Google Scholar
• Crawford Y, Kasman I, Yu L, PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21-34
   PubMed Web of Science ®Google Scholar
• Langerak A, van der Linden-van Beurden CA, Versnel MA. Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochem Biophys Acta 1996;1305:63-70
   PubMed Web of Science ®Google Scholar
• Bertino P, Porta C, Barbone D, Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007;62:690-5
   PubMed Web of Science ®Google Scholar
• Bertino P, Piccardi F, Porta C, Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008;14:541-8
   PubMed Web of Science ®Google Scholar
• Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59:149-50
   PubMed Web of Science ®Google Scholar
• Mathy A, Baas P, Dalesio O, Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005;50:83-6
   PubMed Web of Science ®Google Scholar
• Millward M, Parnis F, Byrne M, Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003;22(228S):abstract 912
   Google Scholar
• Villano JL, Husain AN, Stadler WM, A phase II trial of imatinib mesylate in patients with malignant mesothelioma (MM) ASCO Annual meeting proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(14S Suppl):7200
   Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95
   PubMed Web of Science ®Google Scholar
• Strizzi L, Vianale G, Catalano A, Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 2001;18:1093-8
   PubMed Web of Science ®Google Scholar
• Edwards JG, Cox G, Andi A, Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001;85:863-8
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Vermeulen PB, Weyler J, Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997;182:211-16
   PubMed Web of Science ®Google Scholar
• Pathak AP, Hochfeld WE, Goodman SL, Pepper MS. Circulating and imaging markers for angiogenesis. Angiogenesis 2008;11:321-35
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG, Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38
   PubMed Web of Science ®Google Scholar
• de Langen AJ, Lubberink M, Boellaard R, Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med 2008;49:1763-8
   PubMed Web of Science ®Google Scholar
• Clamp AR, Jayson GC. The role of imaging in the clinical development of antiangiogenic agents. From: cancer drug discovery and development. In: Teicher BA, Ellis LM, editors. Antiangiogenic Agents in Cancer Therapy. Humana Press; Totowa, NJ: 2008
   Google Scholar
• Giesel FL, Choyke PL, Mehndiratta A, Pharmacokinetic analysis of malignant pleural mesothelioma : initial results of tumor microcirculation and its correlation to microvessel density (CD-34). Acad Radiol 2008;15:563-70
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical application of angiogenesis. Nature 2011;473:298-307
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603
   PubMed Web of Science ®Google Scholar